First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis

NCT01674309 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of Rectum

Interventions

DRUG: FOLFORINOX

Sponsor

Federation Francophone de Cancerologie Digestive